(3E)-3-[(2-chloro-1H-benzo[g]indol-3-yl)methylidene]-5-fluoro-1H-indol-2-one | 1237738-55-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (3E)-3-[(2-chloro-1H-benzo[g]indol-3-yl)methylidene]-5-fluoro-1H-indol-2-one
• CAS: 1237738-55-4
• 化学式: C₂₁H₁₂ClFN₂O
• 分子量: 362.79
• InChiKey: NYJRKQBUMXDYLS-LICLKQGHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-氟吲哚-2-酮 、 2-chloro-1H-benzo[g]indole-3-carbaldehyde 在 盐酸 作用下， 以 溶剂黄146 为溶剂， 反应 24.0h， 生成 (3E)-3-[(2-chloro-1H-benzo[g]indol-3-yl)methylidene]-5-fluoro-1H-indol-2-one
  参考文献：
  名称：

  Substituted E-3-(3-Indolylmethylene)-1,3-dihydroindol-2-ones with Antitumor Activity. In Depth Study of the Effect on Growth of Breast Cancer Cells

  摘要：

  The synthesis of new substituted E-3-(3-indolylmethylene)-1,3-dihydroindo1-2-ones is reported. The antitumor activity was evaluated according to protocols available at the National Cancer Institute (NCI), Bethesda, MD. Structure activity relationships are discussed. The action of selected compounds was investigated in MCF-7 breast cancer cells. The ability of these derivatives to inhibit cellular proliferation was accompanied by increased level of p53 and its transcriptional targets p21 and Bax, interference in the cell cycle progression with cell accumulation in the G2/M phase, and activation of apoptosis.

  DOI：

  10.1021/jm1007165

文献信息

• Substituted <i>E</i>-3-(3-Indolylmethylene)-1,3-dihydroindol-2-ones with Antitumor Activity. In Depth Study of the Effect on Growth of Breast Cancer Cells
  作者：Aldo Andreani、Stefania Bellini、Silvia Burnelli、Massimiliano Granaiola、Alberto Leoni、Alessandra Locatelli、Rita Morigi、Mirella Rambaldi、Lucilla Varoli、Natalia Calonghi、Concettina Cappadone、Maddalena Zini、Claudio Stefanelli、Lanfranco Masotti、Robert H. Shoemaker

  DOI：10.1021/jm1007165

  日期：2010.8.12

  The synthesis of new substituted E-3-(3-indolylmethylene)-1,3-dihydroindo1-2-ones is reported. The antitumor activity was evaluated according to protocols available at the National Cancer Institute (NCI), Bethesda, MD. Structure activity relationships are discussed. The action of selected compounds was investigated in MCF-7 breast cancer cells. The ability of these derivatives to inhibit cellular proliferation was accompanied by increased level of p53 and its transcriptional targets p21 and Bax, interference in the cell cycle progression with cell accumulation in the G2/M phase, and activation of apoptosis.